ID   MACD1_HUMAN             Reviewed;         325 AA.
AC   Q9BQ69; Q9UH96;
DT   16-JUN-2003, integrated into UniProtKB/Swiss-Prot.
DT   16-JUN-2003, sequence version 2.
DT   15-MAR-2017, entry version 127.
DE   RecName: Full=O-acetyl-ADP-ribose deacetylase MACROD1;
DE            EC=3.2.2.-;
DE            EC=3.5.1.-;
DE   AltName: Full=MACRO domain-containing protein 1;
DE   AltName: Full=Protein LRP16;
DE   AltName: Full=[Protein ADP-ribosylglutamate] hydrolase;
GN   Name=MACROD1; Synonyms=LRP16;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lymphocyte;
RX   PubMed=12578638;
RA   Han W.-D., Yu L., Lou F.D., Wang Q.S., Zhao Y., Shi Z.J., Jin H.J.;
RT   "The application of RACE technique to clone the full-length cDNA of a
RT   novel leukemia associated gene LRP16.";
RL   Zhongguo Shi Yan Xue Ye Xue Za Zhi 9:18-21(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   INDUCTION.
RX   PubMed=12790785; DOI=10.1677/erc.0.0100217;
RA   Han W.-D., Mu Y.-M., Lu X.-C., Xu Z.-M., Li X.-J., Yu L., Song H.-J.,
RA   Li M., Lu J.-M., Zhao Y.-L., Pan C.-Y.;
RT   "Up-regulation of LRP16 mRNA by 17beta-estradiol through activation of
RT   estrogen receptor alpha (ERalpha), but not ERbeta, and promotion of
RT   human breast cancer MCF-7 cell proliferation: a preliminary report.";
RL   Endocr. Relat. Cancer 10:217-224(2003).
RN   [4]
RP   INDUCTION, AND FUNCTION.
RX   PubMed=17893710; DOI=10.1038/cr.2007.79;
RA   Meng Y.G., Han W.-D., Zhao Y.-L., Huang K., Si Y.-L., Wu Z.-Q.,
RA   Mu Y.-M.;
RT   "Induction of the LRP16 gene by estrogen promotes the invasive growth
RT   of Ishikawa human endometrial cancer cells through the downregulation
RT   of E-cadherin.";
RL   Cell Res. 17:869-880(2007).
RN   [5]
RP   INTERACTION WITH ESR1, AND FUNCTION.
RX   PubMed=17914104; DOI=10.1677/ERC-06-0082;
RA   Han W.-D., Zhao Y.-L., Meng Y.G., Zang L., Wu Z.-Q., Li Q., Si Y.-L.,
RA   Huang K., Ba J.-M., Morinaga H., Nomura M., Mu Y.-M.;
RT   "Estrogenically regulated LRP16 interacts with estrogen receptor alpha
RT   and enhances the receptor's transcriptional activity.";
RL   Endocr. Relat. Cancer 14:741-753(2007).
RN   [6]
RP   CHROMOSOMAL TRANSLOCATION WITH RUNX1.
RX   PubMed=17532767; DOI=10.1111/j.1600-0609.2007.00858.x;
RA   Imagama S., Abe A., Suzuki M., Hayakawa F., Katsumi A., Emi N.,
RA   Kiyoi H., Naoe T.;
RT   "LRP16 is fused to RUNX1 in monocytic leukemia cell line with
RT   t(11;21)(q13;q22).";
RL   Eur. J. Haematol. 79:25-31(2007).
RN   [7]
RP   FUNCTION, INTERACTION WITH ANDROGENE RECEPTOR, AND INDUCTION BY
RP   ANDROGEN.
RX   PubMed=19022849; DOI=10.1677/ERC-08-0150;
RA   Yang J., Zhao Y.-L., Wu Z.-Q., Si Y.-L., Meng Y.G., Fu X.B., Mu Y.-M.,
RA   Han W.-D.;
RT   "The single-macro domain protein LRP16 is an essential cofactor of
RT   androgen receptor.";
RL   Endocr. Relat. Cancer 16:139-153(2009).
RN   [8]
RP   INDUCTION, AND FUNCTION.
RX   PubMed=19403568; DOI=10.1677/JOE-09-0054;
RA   Tian L., Wu Z., Zhao Y., Meng Y., Si Y., Fu X., Mu Y., Han W.;
RT   "Differential induction of LRP16 by liganded and unliganded estrogen
RT   receptor alpha in SKOV3 ovarian carcinoma cells.";
RL   J. Endocrinol. 202:167-177(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASN-174; ASP-184
RP   AND GLY-270.
RX   PubMed=23474712; DOI=10.1038/nsmb.2523;
RA   Jankevicius G., Hassler M., Golia B., Rybin V., Zacharias M.,
RA   Timinszky G., Ladurner A.G.;
RT   "A family of macrodomain proteins reverses cellular mono-ADP-
RT   ribosylation.";
RL   Nat. Struct. Mol. Biol. 20:508-514(2013).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 91-325, FUNCTION, CATALYTIC
RP   ACTIVITY, MUTAGENESIS OF ASP-160; ASP-167; ASN-171; ASN-174; ASP-184;
RP   HIS-188; SER-268 AND GLY-270, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   ENZYME REGULATION.
RX   PubMed=21257746; DOI=10.1074/jbc.M110.206771;
RA   Chen D., Vollmar M., Rossi M.N., Phillips C., Kraehenbuehl R.,
RA   Slade D., Mehrotra P.V., von Delft F., Crosthwaite S.K., Gileadi O.,
RA   Denu J.M., Ahel I.;
RT   "Identification of macrodomain proteins as novel O-acetyl-ADP-ribose
RT   deacetylases.";
RL   J. Biol. Chem. 286:13261-13271(2011).
CC   -!- FUNCTION: Removes ADP-ribose from glutamate residues in proteins
CC       bearing a single ADP-ribose moiety. Inactive towards proteins
CC       bearing poly-ADP-ribose. Deacetylates O-acetyl-ADP ribose, a
CC       signaling molecule generated by the deacetylation of acetylated
CC       lysine residues in histones and other proteins. Plays a role in
CC       estrogen signaling. Binds to androgen receptor (AR) and amplifies
CC       the transactivation function of AR in response to androgen. May
CC       play an important role in carcinogenesis and/or progression of
CC       hormone-dependent cancers by feed-forward mechanism that activates
CC       ESR1 transactivation. Could be an ESR1 coactivator, providing a
CC       positive feedback regulatory loop for ESR1 signal transduction.
CC       Could be involved in invasive growth by down-regulating CDH1 in
CC       endometrial cancer cells. Enhances ESR1-mediated transcription
CC       activity. {ECO:0000269|PubMed:17893710,
CC       ECO:0000269|PubMed:17914104, ECO:0000269|PubMed:19022849,
CC       ECO:0000269|PubMed:19403568, ECO:0000269|PubMed:21257746,
CC       ECO:0000269|PubMed:23474712}.
CC   -!- ENZYME REGULATION: Subject to competitive inhibition by the
CC       product ADP-ribose. {ECO:0000269|PubMed:21257746}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=373 uM for O-acetyl-ADP-ribose {ECO:0000269|PubMed:21257746};
CC   -!- SUBUNIT: Interacts with ESR1; Interacts in a manner that is
CC       estrogen independent but is enhanced by estrogen. Interacts (via
CC       macro domain) with AR. {ECO:0000269|PubMed:17914104,
CC       ECO:0000269|PubMed:19022849}.
CC   -!- INTERACTION:
CC       P03372:ESR1; NbExp=4; IntAct=EBI-5324932, EBI-78473;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:23474712}.
CC       Note=Recruited to DNA lesions, probably via mono-APD-ribosylated
CC       proteins.
CC   -!- INDUCTION: Overexpressed by estrogens in breast cancer MCF-7
CC       cells, probably via an activation of nuclear receptors for
CC       steroids (ESR1 but not ESR2). Significantly increased by estrogens
CC       in ESR1-positive Ishikawa endometrial cancer cells. Up-regulated
CC       in 17-beta-estradiol-responsive BG-1 ovarian cancer cells but
CC       down-regulated in estrogen-resistant SKOV3 ovarian cancer cells.
CC       Induced by androgen. {ECO:0000269|PubMed:12790785,
CC       ECO:0000269|PubMed:17893710, ECO:0000269|PubMed:19022849,
CC       ECO:0000269|PubMed:19403568}.
CC   -!- DISEASE: Note=A chromosomal aberration involving MACROD1 is found
CC       in acute leukemia. Translocation t(11;21)(q13;q22) that forms a
CC       RUNX1-MACROD1 fusion protein. {ECO:0000269|PubMed:17532767}.
CC   -!- MISCELLANEOUS: Overexpression may promote MCF-7 cells
CC       proliferation. There is an approximate one-third increase of the
CC       invasive capacity of MACROD1-overexpressing cells. The expression
CC       of CDH1 is repressed by MACROD1. Further analyzes demonstrats that
CC       MACROD1 inhibits CDH1 transactivation in a dose dependent manner.
CC       Inhibition is abolished by estrogen deprivation, indicating that
CC       the down-regulation of CDH1 transcription by MACROD1 requires ESR1
CC       mediation. Binding of ESR1 to the CDH1 promoter is antagonized by
CC       MACROD1, suggesting that MACROD1 could interfere with ESR1-
CC       mediated transcription. Knockdown of MACROD1 leads to impaired AR
CC       function and greatly attenuates the coactivation of AR by other AR
CC       coactivators such as UXT and NCOA1. This interference also
CC       markedly inhibits the androgen-stimulated proliferation of
CC       androgen-sensitive LNCaP prostate cancer cells. MACROD1 knockdown
CC       does not significantly affect the growth rate of AR-negative PC-3
CC       prostate cancer cells.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH03188.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAH03188.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MACROD1ID50947ch11q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF202922; AAF15294.2; -; mRNA.
DR   EMBL; BC000270; AAH00270.2; -; mRNA.
DR   EMBL; BC003188; AAH03188.1; ALT_INIT; mRNA.
DR   EMBL; BC007297; AAH07297.1; -; mRNA.
DR   EMBL; BC008316; AAH08316.1; -; mRNA.
DR   CCDS; CCDS8056.1; -.
DR   RefSeq; NP_054786.2; NM_014067.3.
DR   UniGene; Hs.602898; -.
DR   PDB; 2X47; X-ray; 1.70 A; A=91-325.
DR   PDBsum; 2X47; -.
DR   ProteinModelPortal; Q9BQ69; -.
DR   SMR; Q9BQ69; -.
DR   BioGrid; 118813; 26.
DR   IntAct; Q9BQ69; 3.
DR   STRING; 9606.ENSP00000255681; -.
DR   iPTMnet; Q9BQ69; -.
DR   PhosphoSitePlus; Q9BQ69; -.
DR   BioMuta; MACROD1; -.
DR   DMDM; 32129719; -.
DR   EPD; Q9BQ69; -.
DR   MaxQB; Q9BQ69; -.
DR   PaxDb; Q9BQ69; -.
DR   PeptideAtlas; Q9BQ69; -.
DR   PRIDE; Q9BQ69; -.
DR   Ensembl; ENST00000255681; ENSP00000255681; ENSG00000133315.
DR   GeneID; 28992; -.
DR   KEGG; hsa:28992; -.
DR   UCSC; uc001nyh.4; human.
DR   CTD; 28992; -.
DR   DisGeNET; 28992; -.
DR   GeneCards; MACROD1; -.
DR   HGNC; HGNC:29598; MACROD1.
DR   HPA; HPA041031; -.
DR   HPA; HPA071075; -.
DR   MIM; 610400; gene.
DR   neXtProt; NX_Q9BQ69; -.
DR   OpenTargets; ENSG00000133315; -.
DR   PharmGKB; PA162394816; -.
DR   eggNOG; KOG2633; Eukaryota.
DR   eggNOG; COG2110; LUCA.
DR   GeneTree; ENSGT00520000055566; -.
DR   HOGENOM; HOG000086960; -.
DR   HOVERGEN; HBG052356; -.
DR   InParanoid; Q9BQ69; -.
DR   OMA; KITCGYR; -.
DR   OrthoDB; EOG091G0NNH; -.
DR   PhylomeDB; Q9BQ69; -.
DR   TreeFam; TF341440; -.
DR   ChiTaRS; MACROD1; human.
DR   EvolutionaryTrace; Q9BQ69; -.
DR   GenomeRNAi; 28992; -.
DR   PRO; PR:Q9BQ69; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000133315; -.
DR   CleanEx; HS_MACROD1; -.
DR   Genevisible; Q9BQ69; HS.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0019213; F:deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0016798; F:hydrolase activity, acting on glycosyl bonds; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0051725; P:protein de-ADP-ribosylation; IDA:UniProtKB.
DR   GO; GO:0042278; P:purine nucleoside metabolic process; IDA:UniProtKB.
DR   InterPro; IPR002589; Macro_dom.
DR   Pfam; PF01661; Macro; 1.
DR   SMART; SM00506; A1pp; 1.
DR   PROSITE; PS51154; MACRO; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Chromosomal rearrangement;
KW   Complete proteome; DNA damage; Hydrolase; Nucleus; Reference proteome.
FT   CHAIN         1    325       O-acetyl-ADP-ribose deacetylase MACROD1.
FT                                /FTId=PRO_0000084485.
FT   DOMAIN      141    322       Macro. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00490}.
FT   REGION      159    161       Substrate binding. {ECO:0000250}.
FT   REGION      172    174       Substrate binding. {ECO:0000250}.
FT   REGION      179    184       Substrate binding. {ECO:0000250}.
FT   REGION      267    273       Substrate binding. {ECO:0000305}.
FT   BINDING     306    306       Substrate. {ECO:0000250}.
FT   SITE        100    100       Breakpoint for translocation to form
FT                                RUNX1-MACROD1.
FT                                {ECO:0000269|PubMed:17532767}.
FT   MOD_RES      96     96       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q922B1}.
FT   MOD_RES     103    103       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q922B1}.
FT   MOD_RES     129    129       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q922B1}.
FT   MOD_RES     163    163       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q922B1}.
FT   MUTAGEN     160    160       D->A: Reduced enzyme activity.
FT                                {ECO:0000269|PubMed:21257746}.
FT   MUTAGEN     167    167       D->A: Reduced enzyme activity.
FT                                {ECO:0000269|PubMed:21257746}.
FT   MUTAGEN     171    171       N->A: Reduced enzyme activity. No
FT                                significant effect on affinity for
FT                                substrate. {ECO:0000269|PubMed:21257746}.
FT   MUTAGEN     174    174       N->A: Slightly reduced ADP-ribosyl
FT                                hydrolase activity; when associated with
FT                                A-184. Reduces O-acetyl-ADP-ribose
FT                                deacetylase activity by 93%; when
FT                                associated with A-184. No significant
FT                                effect on affinity for substrate.
FT                                {ECO:0000269|PubMed:21257746,
FT                                ECO:0000269|PubMed:23474712}.
FT   MUTAGEN     184    184       D->A: Slightly reduced ADP-ribosyl
FT                                hydrolase activity; when associated with
FT                                A-174. Reduces O-acetyl-ADP-ribose
FT                                deacetylase activity by 93%; when
FT                                associated with A-174. No significant
FT                                effect on affinity for substrate.
FT                                {ECO:0000269|PubMed:21257746,
FT                                ECO:0000269|PubMed:23474712}.
FT   MUTAGEN     188    188       H->A: Reduced enzyme activity.
FT                                {ECO:0000269|PubMed:21257746}.
FT   MUTAGEN     268    268       S->A: No significant effect on enzyme
FT                                activity. {ECO:0000269|PubMed:21257746}.
FT   MUTAGEN     270    270       G->E: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:21257746,
FT                                ECO:0000269|PubMed:23474712}.
FT   HELIX        94    103       {ECO:0000244|PDB:2X47}.
FT   HELIX       107    110       {ECO:0000244|PDB:2X47}.
FT   HELIX       111    113       {ECO:0000244|PDB:2X47}.
FT   HELIX       122    124       {ECO:0000244|PDB:2X47}.
FT   HELIX       128    132       {ECO:0000244|PDB:2X47}.
FT   HELIX       148    151       {ECO:0000244|PDB:2X47}.
FT   STRAND      154    159       {ECO:0000244|PDB:2X47}.
FT   HELIX       161    163       {ECO:0000244|PDB:2X47}.
FT   STRAND      164    172       {ECO:0000244|PDB:2X47}.
FT   HELIX       182    191       {ECO:0000244|PDB:2X47}.
FT   HELIX       193    200       {ECO:0000244|PDB:2X47}.
FT   STRAND      210    214       {ECO:0000244|PDB:2X47}.
FT   STRAND      218    227       {ECO:0000244|PDB:2X47}.
FT   HELIX       237    256       {ECO:0000244|PDB:2X47}.
FT   STRAND      261    264       {ECO:0000244|PDB:2X47}.
FT   HELIX       276    294       {ECO:0000244|PDB:2X47}.
FT   HELIX       295    297       {ECO:0000244|PDB:2X47}.
FT   STRAND      299    305       {ECO:0000244|PDB:2X47}.
FT   HELIX       308    321       {ECO:0000244|PDB:2X47}.
SQ   SEQUENCE   325 AA;  35505 MW;  82294BFC904FA4D0 CRC64;
     MSLQSRLSGR LAQLRAAGQL LVPPRPRPGH LAGATRTRSS TCGPPAFLGV FGRRARTSAG
     VGAWGAAAVG RTAGVRTWAP LAMAAKVDLS TSTDWKEAKS FLKGLSDKQR EEHYFCKDFV
     RLKKIPTWKE MAKGVAVKVE EPRYKKDKQL NEKISLLRSD ITKLEVDAIV NAANSSLLGG
     GGVDGCIHRA AGPLLTDECR TLQSCKTGKA KITGGYRLPA KYVIHTVGPI AYGEPSASQA
     AELRSCYLSS LDLLLEHRLR SVAFPCISTG VFGYPCEAAA EIVLATLREW LEQHKDKVDR
     LIICVFLEKD EDIYRSRLPH YFPVA
//
